+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Research, Commercialized, Musculoskeletal Disorders), by Therapy Type (Autologous, Allogeneic), by Region, and Segment Forecasts, 2020 - 2027

  • ID: 4700911
  • Report
  • February 2020
  • Region: Global
  • 125 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • ANTEROGEN.CO.,LTD
  • Celgene Corporation
  • Cells for Cells
  • Fibrocell Science, Inc.
  • Kolon TissueGene, Inc.
  • MEDIPOST
  • MORE
The global cell therapy market size is expected to reach USD 8.8 billion by 2027 at a CAGR of 5.4% over the forecast period. Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and clinical translation. Moreover, rapid advances in stem cell research hold the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. These factors have boosted revenue growth for the market.

Currently, there are a limited number of FDA-approved commercial stem and non-stem cell therapies in the market. Furthermore, LAVIV (Azficel-T), manufactured and commercialized by Fibrocell Technologies, witnessed revenue wind-down in the past years. Key developers are making substantial investments in the adoption of advanced technologies to address the aforementioned challenges.

The introduction of proprietary cell lines is recognized as the primary means by which a single cell can be exploited for the production of a robust portfolio of candidates. Companies are leveraging new technologies not only for the expansion of their product portfolio but also for establishing out-licensing or co-development agreements with other entities to support their product development programs.

For instance, MaxCyte has more than 40 high-value cellular therapy partnership programs within immune-oncology, regenerative medicine, and gene editing, including fifteen clinical-stage programs. Increase in the number of collaborations between entities for product commercialization is anticipated to accelerate market revenue to a major extent in the coming years.

In Asia Pacific, the market is anticipated to witness significant growth over the forecast period. This is attributed to rising awareness cellular therapies among patients and healthcare entities in chronic disease management. In addition, availability of therapeutic treatment at lower prices is also driving the regional market. Japan is likely to witness fast growth over the forecast period attributed to increasing research activities on regenerative medicine.

Further key findings from the report suggest:
  • The clinical-use segment accounted for low revenue share due to stringent regulations and non- commercial viability of some products
  • However, the expanding knowledge over the commercial potential of cellular therapies is anticipated to result in the commercialization of a large number of products in the coming years
  • On the contrary, the research-use segment accounted for the largest revenue share in 2019 owing to increase in research activities to explore the potential of the therapy in substantially improving disease management
  • Furthermore, an increase in funding to explore the potential of these therapies has contributed to the large share of the research segment
  • Allogenic therapies dominated the revenue share in 2019 owing to relatively lower relapse rates and growth in stem cell banking activities
  • This is due to the high price and a large number of companies involved in the development of allogenic therapies
  • Moreover, several companies are preparing to shift their business towards allogeneic therapy product development, resulting in significant revenue growth in this segment
  • Autologous therapies are estimated to grow at the fastest pace during the forecast period
  • Lack of donors and low affordability of allogeneic therapies are two key factors contributing to the increase in adoption of autologous therapies
  • Considering the growing share of the cell therapy market in the biopharma industry, the companies are striving to gain a competitive advantage
  • Vericel Corporation, JCR Pharmaceuticals Co. Ltd., MEDIPOST, and Osiris Therapeutics, Inc. are some key players operating in the market
  • These companies are engaged in the expansion of their product portfolio, either through product development or acquisition of other players operating in the space.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ANTEROGEN.CO.,LTD
  • Celgene Corporation
  • Cells for Cells
  • Fibrocell Science, Inc.
  • Kolon TissueGene, Inc.
  • MEDIPOST
  • MORE
Chapter 1 Executive Summary

1.1 Market Snapshot

Chapter 2 Research Methodology
2.1 Information Procurement
2.1.1 Purchased Database
2.1.2 Internal Database
2.2 Data Analysis
2.3 Market Formulation & Validation
2.4 Approaches for Market Estimation
2.4.1 Approach 1: Commodity Flow & Bottom Up Approach
2.4.2 Approach 2: Top Down and Parent Market Analysis

Chapter 3 Cell Therapy Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Rise in number of clinical studies pertaining to the development of cellular therapies
3.1.1.2 Rising adoption of regenerative medicine
3.1.1.3 Introduction of novel platforms and technologies
3.1.2 Market restraint analysis
3.1.2.1 Ethical concerns related to stem cell research
3.1.2.2 Clinical issues pertaining to development & implementation of cell therapy
3.1.2.2.1 Manufacturing issues
3.1.2.2.2 Genetic instability
3.1.2.2.3 Stem cell culture condition
3.1.2.2.4 Stem cell distribution after transplant
3.1.2.2.5 Immunological rejection
3.1.2.2.6 Challenges associated with allogeneic mode of transplantation
3.2 Penetration & Growth Prospect Mapping For Therapy Type, 2019
3.3 Cell Therapy Market (Stem & Non-stem Cells)-Swot Analysis, by Factor (Political & Legal, Economic and Technological)
3.4 Industry Analysis - Porter’s
3.5 Cell Therapy Market (Stem & Non-stem Cells)-Regulatory Landscape

Chapter 4 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Use-type Estimates & Trend Analysis
4.1 Cell Therapy Market (Stem & Non-stem Cells): Use-type Movement Analysis
4.2 Clinical-use
4.2.1 Global cell therapy market (stem & non-stem cells) for clinical-use, 2016 - 2027 (USD Million)
4.2.2 Cell therapy market (stem & non-stem cells) for clinical-use, by therapeutic area
4.2.2.1 Malignancies
4.2.2.1.1 Global cell therapy market (stem & non-stem cells) for malignancies, 2016 - 2027 (USD Million)
4.2.2.2 Musculoskeletal disorders
4.2.2.2.1 Global cell therapy market (stem & non-stem cells) for Musculoskeletal disorders, 2016 - 2027 (USD Million)
4.2.2.3 Autoimmune disorders
4.2.2.3.1 Global cell therapy market (stem & non-stem cells) for autoimmune disorders, 2016 - 2027 (USD Million)
4.2.2.4 Dermatology
4.2.2.4.1 Global cell therapy market (stem & non-stem cells) for dermatology, 2016 - 2027 (USD Million)
4.2.2.5 Others
4.2.2.5.1 Global cell therapy market (stem & non-stem cells) for other therapeutic areas, 2016 - 2027 (USD Million)
4.2.3 Cell therapy market (stem & non-stem cells) for clinical-use, by cell type
4.2.3.1 Stem cell therapies
4.2.3.1.1 Global stem cell therapies market, 2016 - 2027 (USD Million)
4.2.3.1.2 Bone marrow, blood, & umbilical cord-derived stem cell therapies
4.2.3.1.3 Adipose-derived stem cell therapies
4.2.3.1.4 Other stem cell therapies
4.2.3.2 Non-stem cell therapies
4.2.3.2.1 Global non-stem cell therapies market, 2016 - 2027 (USD Million)
4.3 Research-use
4.3.1 Global cell therapy market (stem & non-stem cells) for research-use, 2016 - 2027 (USD Million)

Chapter 5 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Therapy Type Estimates & Trend Analysis
5.1 Cell Therapy Market (Stem & Non-stem Cells): Therapy Type Movement Analysis
5.2 Allogeneic Therapies
5.2.1 Global cell therapy market (stem & non-stem cells) for allogeneic therapies, 2016 - 2027 (USD Million)
5.3 Autologous Therapies
5.3.1 Global cell therapy market (stem & non-stem cells) for autologous therapies, 2016 - 2027 (USD Million)

Chapter 6 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Regional Estimates & Trend Analysis, by Product
6.1 Cell Therapy Market (Stem & Non-stem Cells) Share by Regional, 2019 & 2027
6.2 North America
6.2.1 North America cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
6.2.2.2 U.S. cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
6.2.3 Canada
6.2.3.1 Canada cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
6.2.3.2 Canada cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
6.3 Europe
6.3.1 Europe cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
6.3.2 Germany
6.3.2.1 Germany cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
6.3.2.2 Germany cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
6.3.3 U.K.
6.3.3.1 U.K. cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
6.3.3.2 U.K. cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
6.4.2 China
6.4.2.1 China cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
6.4.2.2 China cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
6.4.3 Japan
6.4.3.1 Japan cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
6.4.3.2 Japan cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
6.5 Latin America
6.5.1 Latin America cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
6.5.2.2 Brazil cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
6.6 MEA
6.6.1 MEA cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
6.6.2.2 South Africa cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)

Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Company Profiles
7.2.1 Kolon TissueGene, Inc.
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 JCR Pharmaceuticals Co., Ltd.
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.2.1 Financial performance of TEMCELL HS Inj
7.2.2.3 Product benchmarking
7.2.2.4 Strategic initiatives
7.2.3 MEDIPOST
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Osiris Therapeutics, Inc.
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Product benchmarking
7.2.5 Stemedica Cell Technologies, Inc.
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 Cells for Cells
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.7 NuVasive, Inc
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.8 Fibrocell Science, Inc.
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 Vericel Corporation
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Product benchmarking
7.2.9.4 Strategic initiatives
7.2.10 PHARMICELL Co., Ltd
7.2.10.1 Company overview
7.2.10.2 Financial performance
7.2.10.3 Product benchmarking
7.2.10.4 Strategic initiatives
7.2.11 ANTEROGEN.CO.,LTD
7.2.11.1 Company overview
7.2.11.2 Financial performance
7.2.11.3 Product benchmarking
7.2.11.4 Strategic initiatives
7.2.12 Celgene Corporation
7.2.12.1 Company overview
7.2.12.2 Financial performance
7.2.12.3 Product benchmarking
7.2.12.4 Strategic Initiatives
Note: Product cover images may vary from those shown
3 of 4
  • Kolon TissueGene, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • MEDIPOST
  • Osiris Therapeutics, Inc.
  • Stemedica Cell Technologies, Inc.
  • Cells for Cells
  • NuVasive, Inc
  • Fibrocell Science, Inc.
  • Vericel Corporation
  • PHARMICELL Co., Ltd
  • ANTEROGEN.CO.,LTD
  • Celgene Corporation
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll